Cannabinoid genotoxicity and congenital anomalies: A convergent synthesis of European and USA data sets

Document Type

Book Chapter

Publication Title

Cannabis Use, Neurobiology, Psychology, and Treatment

First Page

71

Last Page

92

Publisher

Elsevier

School

School of Medical and Health Sciences

RAS ID

60767

Comments

Reece, A. S., & Hulse, G. K. (2023). Cannabinoid genotoxicity and congenital anomalies: A convergent synthesis of European and USA data sets. In C. R. martin, V. B. Patel & V. R. Preedy (Eds.), Cannabis Use, Neurobiology, Psychology, and Treatment (pp.71-92). Elsevier/Academic Press https://doi.org/10.1016/B978-0-323-89862-1.00040-4

Abstract

The USA and European data sets for congenital anomalies together represent the bulk of the publicly available global database, which allows the quantitative assessment of cannabinoid- and substance-related teratogenesis. All 45 (100%) congenital anomalies found to be cannabis-related on bivariate analysis in USA were confirmed from the European databases. 89 of 95 (93.7%) anomalies assessed in Europe were found on bivariate analysis to be cannabis-related. 65 of 69 (94.2%) European anomalies with adequate data for external assessment could be confirmed. Cardiovascular, chromosomal facial, limb, central nervous system, gastrointestinal, and uronephrological anomalies were well represented. 388MB (12.9%) of the human genome is directly implicated. Data demonstrate great internal and external validity and indicate that cannabinoid mutagenesis and genotoxicity are powerful and carry major genomic, epigenomic, and transgenerational impacts. Along with exponential dose-response curves, the data strongly indicate careful control of cannabinoid exposure in line with policies for other major genotoxic compounds.

DOI

10.1016/B978-0-323-89862-1.00040-4

Access Rights

subscription content

Link to Full Text

Share

 
COinS